Key clinical point: Dupilumab led to clinically meaningful improvements in the severity of atopic dermatitis (AD) and was well tolerated in adolescents and children with moderate-to-severe AD.
Major finding: The mean improvement in the Eczema Area and Severity Index (EASI) was 59.6% at week 12-24 and 77.0% at week 36-48 (both P < .001), with all patients achieving ≥75% improvement in EASI score after a year or more of receiving dupilumab. Adverse events like conjunctivitis (5.6%) and joint pain (2.2%) were reported by 13.5% of patients.
Study details: Findings are from a retrospective observational study including 89 children and adolescents aged < 18 years with moderate-to-severe AD who initiated dupilumab treatment.
Disclosures: This study was funded by Pediatric Dermatology Research Alliance. Some authors declared serving as consultants or receiving research funds from several sources.
Source: Pagan AD et al. Dupilumab improves clinical scores in children and adolescents with moderate-to-severe atopic dermatitis: A real-world, single-center study. J Allergy Clin Immunol Pract. 2022 (Jun 23). Doi: 10.1016/j.jaip.2022.06.014